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ABSTRACT
Background: Laparoscopic sleeve gastrectomy is becom-
ing a popular procedure for the morbidly obese patient.
Its utilization as a standalone procedure has good results
with weight loss in short- and midterm reports. The aim of
this study was to assess our technique and whether it
warranted any modifications in the early postoperative
period.
Methods: Our first 100 consecutive patients undergoing
laparoscopic sleeve gastrectomy were retrospectively re-
viewed. Data analysis was conducted at 3 and 6 months to
assess the percentage of excess body weight loss and
comorbidity status change.
Results: The percentage of excess body weight loss at the
3- and 6-month marks was 34.2% and 49.1%, respectively.
Comorbidities were also improved at the 3- and 6-month
marks. Hypertension resolved in 38%, hyperlipidemia re-
solved in 19%, and diabetes in 46%. Complication rate
during the first 6 months was 10%. Major complications
included 2 patients with postoperative bleeding, 2 pa-
tients with acute renal failure from dehydration, and 1
postoperative bleeding patient who developed a gastric
fistula. No surgical reintervention was required for any
complication.
Conclusion: Our technique is a safe method that is easily
reproducible and does not require any modification. Lapa-
roscopic sleeve gastrectomy is an excellent surgical option
with a low complication rate.
Key Words: Gastric bypass, obesity, gastrectomy, comor-
bidity.
INTRODUCTION
Laparoscopic sleeve gastrectomy (LSG) is a lesser cur-
vature based, subtotal gastric resection used in the
surgical treatment of morbid obesity. LSG is a restrictive
bariatric procedure in which approximately 80% of
the stomach is removed, creating a cylindrical “sleeve”
like conduit (Figure 1). The vagus nerves and pylorus
are preserved, limiting the problems associated with func-
tional gastric outlet obstruction and dumping syndrome.1,2
Historically, sleeve gastrectomy was used as the first part
of a 2-staged bariatric procedure to reduce the morbidity
and mortality for high-risk patients including the super-
super obese (BMI60kg/m
2). LSG is also the gastric com-
ponent of the malabsorptive bariatric procedure, biliopan-
creatic diversion with duodenal switch (BPD/DS).
Although not reversible, LSG can be converted to a
Roux-en Y gastric bypass or BPD/DS.3 Recent studies
have shown promising results with LSG as a single-step
procedure in the surgical treatment for morbid obesity. Its
reproducibility and low complication rate make it a viable
option for morbid obesity surgery.
The authors present their standardized surgical technique
and early postoperative results at 3 and 6 months of their
first 100 consecutive patients who underwent LSG from
November 2006 to July 2008. We wished to evaluate
whether this method proved to be efficacious and with
few complications. In this manner, the technical success
of the procedure could be assessed.
MATERIALS AND METHODS
Patient Selection
The data for 100 consecutive patients undergoing LSG
between November 2006 and July 2008 were analyzed
prospectively. All patients were evaluated at the office of
the Surgeons Group of Baton Rouge. Each LSG was per-
formed by 1 of 2 surgeons in private practice with assis-
tance from a fellow. Both surgeons previously had been
performing laparoscopic gastric bypass (LGB) and lapa-
roscopic adjustable gastric band (LAGB).
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SCIENTIFIC PAPERAny patient with a BMI40kg/m
2 or 35kg/m
2 with se-
vere comorbidity was offered LSG, LGB, or LAGB as a
surgical option for morbid obesity. Each patient under-
went a standardized workup including medical clearance,
psychiatric and nutritional evaluation, preoperative imag-
ing, and standard laboratory examinations. Patients were
also evaluated for previous attempts at weight loss using
other modalities.
Patients had scheduled postoperative office visits at 1
week and 3 weeks, then at 3 months and 6 months with
the intent to follow-up at 9, 12, 18, and 24 months. Data
collected included patient demographics, past medical
history, comorbidities, preoperative weight and BMI, op-
erative data (operating time, complications, and conver-
sion), and morbidity/mortality rates. Postoperative data
analysis included percentage of excess weight loss and
change in comorbidity status.
Surgical Technique
All patients received preoperative intravenous antibiotics
and DVT prophylaxis with unfractionated heparin and
sequential compression devices. Patients were placed in a
supine position with arms out at roughly 90 degrees and
in a steep reverse Trendelenburg. Local anesthesia was
used before all skin incisions. An initial 5-mm trocar was
placed in the midline approximately 15cm below the
xiphoid process. Access to the peritoneal cavity was
gained under direct vision.
Pneumoperitoneum was achieved, and then a 30-degree
laparoscope was used to assist with the placement of the
other trocars. Five trocars (Figure 2) were placed in the
upper abdomen: 2 left upper quadrant trocars both 5mm,
and 2 right upper quadrant trocars, a 5mm (lateral) and a
15mm (medial) for use of the stapler and an extraction site
for the resected stomach. The liver was retracted antero-
superiorly using a Nathanson Liver retractor (Cook Med-
ical, Bloomington, Indiana).
First, the attachments at the Angle of His were divided by
using electrocautery. Next, dissection of the omentum off
the greater curvature of the stomach was initiated 5cm to
6cm proximal to the pylorus and continued to the Angle of
His. Care was taken to preserve the gastroepiploic vessels.
A 34-French (F) bougie was passed down the esophagus,
along the lesser curvature and through the pylorus if
feasible. The sleeve gastrectomy was created using a
60-mm Echelon (Ethicon, Cincinnati, Ohio) stapling de-
vice beginning from the point 5cm to 6cm proximal to the
pylorus and continuing to the Angle of His, tightly abut-
ting the bougie. Graduated staple height loads (based on
tissue thickness) with Seamguard (WL Gore and Associ-
ates, Flagstaff, Arizona) reinforcements were used.
The antrum distal to the staple line or jejunum near the
ligament of Treitz was then clamped, and a saline sub-
mersion test was performed to assess for potential leaks.
The resected stomach was delivered through the 15-mm
trocar site, and the fascial defect was closed. Pneumoperi-
toneum was relieved, and all trocars were removed.
At the end of the procedure, patients were transferred to
the postanesthesia care unit and then the surgical unit. A
Figure 1. Schematic illustration of Sleeve Gastrectomy.
Figure 2. Typical trocar placement.
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started immediately. On the morning of postoperative day
1, patients received a water-soluble upper gastrointestinal
radiological examination (Figure 3) to evaluate for ex-
travasation or obstruction of contrast. The majority of
patients were then discharged to home that same day.
RESULTS
Preoperative Findings
Included in the study were 100 consecutive patients who
underwent sleeve gastrectomy from November 2006 to
July 2008. Data were collected prospectively. Patient de-
mographics are depicted in Table 1.
Operative Findings
All 100 cases were completed laparoscopically with an
average operative time of 83.3 minutes (range, 42–210).
No iatrogenic injuries occurred in this series of patients.
No surgical bleeding occurred within the peritoneal cav-
ity. No clinical leaks were identified intraoperatively using
the saline submersion test.
Postoperative Findings
Weight Loss
The average excess weight loss percentage were 34.2%
(range, 21 to 63) and 49.1% (range, 28 to 95) at 3 and 6
months, respectively. Average BMI at 3 and 6 months was
38.0 (range, 26.9 to 64.6) and 34.2 (range, 23.2 to 58.7).
This corresponded to an average change in BMI of
8.4kg/m
2 and 12.2kg/m
2 respectively at 3 and 6 months.
Comorbidities
Comorbidity status was assessed at each follow-up visit.
Improvements in comorbidities had occurred if either a
lower dosage of medication was required or patients
needed fewer medications to manage the comorbidity.
Resolution of the comorbidity was defined as no longer
requiring medical therapy. At the 6-month period, hyper-
tension resolved in 17 (38%) and improved in 11 (24%)
patients, hyperlipidemia resolved in 5 (19%) and im-
proved in 3 (11%), and diabetes resolved in 19 (46%) and
improved in 2 (5%).
Complications
Complications were stratified into minor and major based
on hospital admission (Table 2). Minor complications did
not warrant hospital admission and were solely managed
in an outpatient setting. The overall complication rate was
10% with no mortalities in our first 100 patients.
Minor complications included nausea with intermittent
vomiting that occurred in 3 patients. All 3 patients had a
negative upper gastrointestinal (UGI) series and a normal
upper endoscopy. Two patients were later diagnosed with
cholelithiasis by ultrasonography, to which their symp-




Male (n12) Female (n88) Total
Avg. Age-years (range) 44.3y (18-58) 44.7 (23-64) 44.7 (18-64)
Avg. Weight-lb (range) 330.7 (271.5-407) 268.7 (197-478.5) 276.1 (197-478)
BMI-kg/m
2 (range) 47.5 (39.3-60.9) 46.3 (34.4-79.6) 46.4 (34.4-79.6)
HTN-n (%) 6 (50) 39 (44) 45 (45)
Hyperlipidemia-n (%) 3 (25) 24 (27) 27 (27)
Type II Diabetes-n (%) 4 (33.3) 37 (42) 41 (41)
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proton pump inhibitor, which alleviated the patient’s nau-
sea. Five patients developed symptomatic cholelithiasis,
including the above 2 who presented with nausea. All 5
patients underwent successful laparoscopic cholecystec-
tomy leading to resolution of symptoms. One patient
developed superficial wound infection at the extraction
port site. This patient was treated with a course of oral
antibiotics for cellulitis and displayed no evidence of in-
fection at the 3-week follow-up. One patient developed
recurrence of a ventral hernia that was initially repaired
primarily at the time of LSG. This patient was asymptom-
atic and underwent a laparoscopic ventral hernia repair
with mesh near the 6-month follow-up without any com-
plications.
Major complications occurred in 4 patients. Postoperative
bleeding occurred in 2 patients, both of whom required a
blood transfusion. These patients were monitored with
serial hemoglobin levels and did not require any further
medical or surgical intervention during their initial admis-
sion. Both patients were discharged home on postopera-
tive day 4 in satisfactory condition. Two patients devel-
oped severe dehydration with acute renal failure due to
intractable nausea and vomiting. Renal failure appropri-
ately responded to intravenous fluids in both patients.
Both patients underwent a UGI, endoscopy, and CT scans,
which could not identify any source of obstruction. One
patient’s dehydration was accounted for by a long-stand-
ing history of severe arthritis, requiring disease modifying
antirheumatic drugs including methotrexate. Incidentally,
renal cell carcinoma was found on a CT scan during the
workup for persistent nausea and anorexia in this patient.
This patient underwent a nephrectomy and a feeding
jejunostomy for nutritional support. The second patient’s
dehydration was caused by vomiting and diarrhea that
occurred within the first month of surgery; however, no
specific cause could be identified. Both patients were
discharged home, tolerating the standard bariatric diet.
One patient developed a gastric fistula and a left upper
quadrant abscess. An initial UGI series on postoperative
day one had no evidence of contrast extravasation. At 7
weeks postsurgery, the workup for the patient’s nausea
and vomiting with oral intake included a UGI and endos-
copy. The UGI did not visualize any extravasation, and the
EGD showed minimal antritis. The patient was continued
on a bariatric diet and advised to eat smaller portions.
Three weeks later, the patient presented with fever and
anorexia. At this time, a CT scan showed a fluid collection
in the left upper quadrant. This was percutaneously
drained, and the patient was placed on parenteral nutri-
tion and intravenous antibiotics. The patient was allowed
to continue her treatment at home once the fevers sub-
sided. A follow-up UGI approximately one month after
drainage visualized extravasation of contrast at the supe-
rior aspect of the staple line. With the aid of the gastro-
enterologist, a covered stent was placed. With decrease in
fistula output, the drain and endoscopic stent were sub-
sequently removed. Total parenteral nutrition was contin-
ued for about 6 weeks. This patient required no further
surgical treatment and is currently on a standard bariatric
diet approximately 1 year from LSG.
DISCUSSION
Results from this series of patients indicate laparoscopic
sleeve gastrectomy to be safe, easily reproducible, and
efficacious as a standalone bariatric procedure. Early
data in our series show excellent weight loss achieved
at the 3- and 6-month mark. In our series, resolution of
morbid obesity (BMI35kg/m
2) occurred in 46% of
patients by 6 months. Presently, there are only a few
series with 100 patients reporting short- and midterm
data up to 2 years. In a recent series of 135 patients,
Fuks et al4 showed percentage excess body weight loss
of 38.6% and 49.4% at 6 months and 1 year, while Nocca
et al5 in 163 patients found the percentage lost in
excessive body weight was 48.9% at 6 months, 59.4% at
1 year (120 patients), and 61.5% at 2 years (98 patients),
similar to our results. In comparing our patients with
patients in these studies, we found no significant dif-
ference in preoperative demographics between the 3
patient populations.
Currently, no recommendations exist on the optimal bou-
gie size for the lesser curve conduit. In our series, a 34F
bougie was chosen to create the gastric sleeve. The cre-
Table 2.
Postoperative Complications




Bleeding requiring transfusion 2
Acute Renal Failure 2
Wound infection 1
Nephrolithiasis 1
Intraabdominal abscess/Gastric fistula 1
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properties of the procedure. There is a concern of post-
operative strictures with the use of smaller bougies and
the need for dilation. This was not seen in any patient in
our series. Many different size bougies (32F to 60F) have
been described for constructing the gastric sleeve, and
some studies have shown no significant difference in
weight loss in the early period.6 This was not the case with
Weiner et al7 who showed that the more restrictive LSG
(bougie sizes of 32F and 44F versus an uncalibrated
sleeve), resulted in maintaining excess weight loss after
the 2-year mark. The study also found that a resected
gastric weight volume 500cc was a predictor in treat-
ment failure or early weight regain.
In comparing LSG to LGB, early data appear to suggest
that LSG is comparable in achieving weight loss in the
morbidly obese patient.8 To our knowledge, only a single
prospective randomized trial has compared LSG with LGB
with data up to 3 years. In this trial, the median EWL was
41.4% after LGB and 57.7% after LSG at 1 year (P0.0004).
EWL at the 3-year mark were 48% after LGB and 66% after
LSG (P0.0025).9 In addition, patients after LSG have
significantly lower plasma ghrelin (hormone involved in
appetite suppression) levels compared with those who
had other restrictive procedures due to resection of the
gastric fundus. The fundus of the stomach contains the
greatest number of ghrelin producing cells. This was ev-
ident in a prospective, double-blinded study by Kara-
mankos et al10 comparing LSG with LGB.
There are multiple factors besides weight loss and low
morbidity and mortality rates that make LSG an enticing
procedure for morbid obesity. In addition, LSG appears to
be a technically easier procedure compared with LGB.
The procedure can be completed laparoscopically in vir-
tually all patients, even those with a large left lobe of the
liver, the extremely obese patient, and those who have
undergone multiple abdominal surgeries.11 LSG has no
enteric anastomosis, and there are no mesenteric defects,
thereby eliminating the risk for internal herniation. LSG is
not associated with dumping syndrome, because of pres-
ervation of the vagus nerves and the pylorus. Further-
more, there are no foreign bodies or the need for percu-
taneous access, as with LAGB. Vitamin, mineral, nutrient,
and drug metabolism may remain unchanged, and the
gastrointestinal tract is easily suitable for endoscopic sur-
veillance and therapeutic procedures.
The complication rates for laparoscopic sleeve gastrec-
tomy range from 0% to 24% with an overall mortality rate
of 0.39%.12–14 A surgical quandary is the patient with a
ventral hernia known preoperatively. Patients who re-
quire a mesh placement may be considered a relative
contraindication based on the clean contamination aspect
of the procedure. Although the risk for recurrence is high,
a primary repair should be performed at the time of LSG
to prevent the risk and complications of incarceration. In
our patient, we elected to wait until the 6-month period to
perform a laparoscopic ventral hernia repair with mesh,
which occurred without complications.
The 2 major complications during bariatric surgery in-
clude bleeding and anastomotic or staple line leaks.15
Recent data suggest that buttressing the staple line with a
bioabsorbable polymer like Seamguard (WL Gore and
Associates, Flagstaff, Arizona) may decrease the incidence
of bleeding and gastric fistulas. Bleeding occurred in 2%
of patients in our study (both intraluminal), while 7.3% in
the study by Silechhia et al.16 In our series, all patients had
buttressing with a bioabsorbable copolymer along the
entire length of the staple line. Meanwhile patients in the
Silechhia series only received a selective area of buttress-
ing, this may have accounted for the difference in bleed-
ing. In 2 separate prospective studies, application of
Seamguard (WL Gore and Associates, Flagstaff, Arizona)
in gastric resections as part of bariatric surgery showed a
significant reduction in blood loss and no evidence of
intraoperative or postoperative leaks.17,18
The complication of gastric fistula is a serious concern.
While it occurred in only a single patient (1%) in our
series, it has been reported as high as 5.1%.4 We did not
identify a specific cause for gastric fistula formation in our
patient. The patient’s preoperative BMI was 44kg/m
2, and
comorbidities included hypertension and diabetes melli-
tus. The patient had a negative saline submersion test
intraoperatively and a negative workup at 7 weeks. This
patient presented with clinical signs of an abscess approx-
imately 10 weeks after surgery.
Could changes in intestinal physiology and local milieu in
the morbidly obese patient have a role in staple-line fail-
ure? Body habitus would suggest that the morbidly obese
patient is well nourished. However, these patients are in
fact malnourished as evident by micronutrient deficiency
reported in multiple studies.19,20 Perhaps ulceration plays
a factor and would account for the late leak.
The ability to determine patients at high risk for staple-line
failure is a difficult task. Although the major risk factor for
gastric fistula remains preoperative BMI 60kg/m
2,4 mul-
tiple studies have shown fistulas to occur in patients with
lower BMIs. Currently, there appears to be no consensus
on how to manage the exposed staple line to prevent
Laparoscopic Sleeve Gastrectomy: Our First 100 Patients, Nath A et al.
JSLS (2010)14:502–508 506leaks and fistulas. Different methods have been utilized
including over-sewing of the staple line. In one study,
over-sewing of LSGs, the leak rate was zero.21 Meanwhile,
Kasalicky et al22 in 61 patients without over-sewing of the
staple line also had a zero leak rate, but the last 24 cases
were buttressed with Surgicel (Johnson and Johnson,
Langhorne, PA) strips. Still other techniques are being
utilized; we and others buttress with absorbable polymers
and in our first 100 cases only had one gastric fistula
occurrence.
Management of gastric fistula remains a dilemma. Surgical
reintervention remains at the forefront and should be used
for any patient with abdominal sepsis. It should be at the
surgeon’s discretion and based on intraoperative findings
whether simple drainage is appropriate or a more defini-
tive procedure can be attempted. Multiple factors should
play a role in the decision-making process. These include
nutritional status, hemodynamic stability, local inflamma-
tory changes, and the ability of a patient to tolerate a
prolonged surgical procedure. We elected to proceed
with percutaneous drainage due to the easy accessibility
of the abscess and no radiological evidence of a leak.
With interval development of a gastric fistula, we at-
tempted nonoperative management with parenteral nutri-
tion and antibiotics. However, our patient continued to
have high fistula output likely due to the patient’s non-
compliance with diet restrictions. We elected to place a
covered stent, a method utilized by others.23 Although our
patient did not require any further surgical intervention,
other methods such as over-sewing the gastric leak site,
injecting fibrin glue, simple drainage, and total gastrec-
tomy have been described.15,24 Although gastric fistula is a
significant complication of LSG, its low occurrence rate is
an acceptable risk for this excellent procedure.
CONCLUSION
The basis of this article was to assess our surgical tech-
nique and the need for any changes in the early postop-
erative period. We found no significant problems and
consider our method to be a safe technique for LSG
without need of modification. Based on early and mid-
term reports, we believe that LSG is an excellent stand-
alone bariatric procedure and should be considered as an
option for the morbidly obese patient seeking surgical
intervention.
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